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Small-cell lung cancer (SCLC) represents a distinct pathological
and clinical entity, accounting for about 15–20% of all lung cancer
cases (Parker et al, 1997). Due to its tendency to disseminate early,
systemic combination chemotherapy has been the cornerstone of
treatment and, depending on initial disease extent, between 80 and
100% of patients achieve objective responses (Ihde et al, 1997). In
localized – limited – disease (LD-SCLC) patients can be cured and
the rate of long-term survivors of 10–15% after 5 years can be
increased to between 15 and 20% by early inclusion of thoracic
irradiation (Pignon et al, 1992; Elias et al, 1997). However, even
in modern chemoradiation protocols, most patients experience
tumour recurrences both locally in the chest as well as at distant
locations – preferably the brain (Arriagada et al, 1992, 1995).
Recent strategies to improve outcome have included: (a) applica-
tion of chemotherapy concurrently with radiation (Takeda et al,
1996); (b) intensification of radiotherapy (hyperfractionated accel-
erated radiation) (Turrisi et al, 1992); (c) combination of both (a)
and (b) with integration of radiation as early as possible; and (d)
increase of chemotherapy dose intensities supported by autologous
bone marrow or peripheral stem cell transplantation (Elias et al,
1993). However, both strategies – to increase local control by
aggressive radiation techniques – as well as an escalation of
systemic treatment intensity – have been hampered by a high rate
of local failures between 30 and 50% (Gray et al, 1995; Elias et al,
1997; Turrisi et al, 1999). Similar to other solid tumours, surgery
may represent the most effective local treatment for dealing with
residual disease at the bulky primary tumour, even though we do
not know which patient subgroups will eventually profit
concerning local control, survival, long-term survival or even cure
(Choi et al, 1997). On this background, we started a phase II trial
in selected SCLC patients, mostly stages IIB, IIIA and IIIB surgi-
cally staged by mediastinoscopy, in whom best results in recent
concurrent chemoradiation protocols have been reported with
15–26% 5-year survival rates (McCracken et al, 1990; Turrisi et al,
1999). Aim of the study was to evaluate feasibility, toxicity and
efficacy of a prognostically orientated approach in patients
consecutively conferred to our institution. Treatment included
upfront cisplatin-based chemotherapy, early concurrent chemo-
radiation with hyperfractionated accelerated radiotherapy in
locally advanced/mediastinal risk stages (IIB/IIIA), as well as
definitive surgery, if possible, adding up to an aggressive
trimodality treatment for the majority of patients.
PATIENTS AND METHODS
Patient selection
Patients with histologically/cytologically proven SCLC were
eligible. Following mediastinoscopy patients with SCLC stages
IB–IIIB were taken onto this trial (Mountain et al, 1997). No
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malignant pleural effusion or with ipsi- or contralateral supraclav-
icular lymph node involvement were excluded. Further eligibility
criteria were performance status (WHO) of less than 2, age
between 18 and 70 years, no prior treatment and no other
malignancy.
Following a complete medical history patients underwent a
general physical examination. A complete blood cell count, serum
chemistry, coagulation tests and urinalysis were performed.
Staging included chest radiographs, computerized tomography
(CT) scans of the chest, upper abdomen and brain, abdominal
ultrasound, radionuclide bone scan, bronchoscopy with biopsies of
prospective resection margins and (cervical) mediastinoscopy with
multiple biopsies of paratracheal, tracheobronchial, subcarinal
nodes and other suspicious mediastinal structures. In case of
suspected pulmonary artery invasion, an angiographic CT scan of
the thorax was performed.
Patients were evaluated in an interdisciplinary conference, and
this risk analysis was repeated preoperatively after restaging and
included cardiopulmonary function tests (Eberhardt et al, 1998).
Characteristics that rendered patients ineligible/functionally
inoperable were a prognosticated post-operative FEV1 of less than
1 litre (Eberhardt et al, 1998). All patients were required to have
normal haematological parameters and adequate organ functions.
Patients with serious concomitant infections were excluded. All
patients were fully informed about the nature and purpose of this
study and gave informed consent. The study protocol had approval
by the local ethics committee.
Prognostically orientated treatment
Eligible patients with stages IB/IIA had four cycles
cisplatin/etoposide (PE), and after the fourth cycle thoracotomy
was planned (Figure 1). Stage IIB/IIIA patients were given three
cycles PE and, during week 10, concurrent chemoradiotherapy
was started combining twice-daily hyperfractionated accelerated
radiotherapy with one cycle of PE. Following this, repeat medi-
astinoscopy was performed in patients with initially involved
mediastinum/mediastinal nodes, and surgery followed 3–5 weeks
after the end of radiation. Patients with N3-disease at medi-
astinoscopy or T4-disease in angiographic CT scans of the chest
(IIIB), were generally not planned for a preoperative approach but
received four chemotherapy cycles and sequential radiation up to
50 Gy in 2-Gy daily fractions. Towards the end of the study period,
patients had the fourth cycle given concurrently to radiation (2 Gy
daily fractions up to between 50 and 60 Gy). During the last year
of the study, two patients with stage IIIB were planned
for a preoperative approach.
Induction chemotherapy
Chemotherapy consisted of cisplatin, 50 mg m–2 as 1-h infusion on
days 1 and 7 (or 8 if outpatient) (Wilke et al, 1988). Prior to
cisplatin, patients had adequate hydration with 1000 ml of 0.9%
normal saline, and diuresis was started with 40 mg furosemide.
Cisplatin was given in 1000 ml 0.9% normal saline. After
cisplatin, patients received 2000 ml 0.9% normal saline together
with 30 mEq magnesium chloride over 2 h. Adequate anti-emetics
(decadronphosphate i.v./ondansetron i.v.) were given with
cisplatin and on the following day. Etoposide was given at 170 mg
m–2 in 500 ml 0.9% normal saline as 1-h infusion on days 3, 4 and
5. The majority of patients was hospitalized for chemotherapy.
Administration of the following cycle on day 22 was postponed if
patients had a white blood cell (WBC) count < 2500 l–1 or a
platelet count < 100 000 l–1 until these values were reached. Dose
reductions were performed as described for our NSCLC-preopera-
tive trial (Eberhardt et al, 1998). In none of the patients included
chemotherapy was supported with haematopoietic growth factors.
Preoperative chemoradiotherapy
A total dose of 45 Gy was given to the primary and the mediastinal
nodes in two daily fractions of 1.5 Gy within 3 weeks. The
minimum time interval between fractions was 6 h. The technique
of radiation delivery was the same as in our NSCLC-trimodality
trial (Eberhardt et al, 1998). Simultaneous chemotherapy was
started on day 2 of radiation (cisplatin 50 mg m–2 days 2 and 9,
etoposide 100 mg m–2 days 4, 5 and 6).
Definitive radiation/chemoradiation
Patients with stage IIIB were generally not planned for inclusion
of surgery (Figure 1). Patients during the first year of the study
received four cycles PE and had radiation therapy sequentially
with conventionally fractionated radiation at 2 Gy per day up to
50 Gy. All following patients had radiation given concurrently to
the fourth chemotherapy cycle. Radiotherapy was fractionated at
2 Gy per day up to between 50 and 60 Gy.
Prophylactic cranial irradiation
Routinely, prophylactic cranial irradiation (PCI) was offered. PCI
was started after the end of the fourth chemotherapy cycle on day
9 of thoracic irradiation in patients with chemoradiation, or was
given following thoracotomy in patients with stages IB and IIA.
A total dose of 30 Gy in 3 weeks was given in daily fractions of
2G y .
Repeat mediastinoscopy/surgery
N2-patients were planned for a repeat mediastinal exploration,
including biopsies of all initially involved mediastinal structures/
nodes. Only patients with negative nodes following induction
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Figure 1 Prognostically orientated treatment schema. Ctx = chemotherapy;
HfRTx = hyperfractionated accelerated radiotherapy; Rtx = radiotherapy; Cis
= cisplatin; Eto = etoposideproceeded to surgery, whereas boost irradiation up to 60 Gy was
offered to patients with persistent mediastinal disease. Three to 5
weeks after end of irradiation, surgery was planned. Surgical
procedures included lobectomies, bilobectomies, sleeve resec-
tions, chest wall resections or pneumonectomies as indicated.
Because our NSCLC study had shown an increased incidence of
stump insufficiencies, bronchial anastomoses were routinely
protected with a flap of intercostal muscle in situations considered
with an increased risk.
Response and toxicity evaluation
Responses were assessed using standard WHO criteria (Miller et
al, 1981). After surgery, patients were staged using UICC criteria.
Toxicities were assessed using the WHO criteria, the RTOG acute
radiation toxicity criteria and the RTOG/European Organization
for Research and Treatment of Cancer (EORTC) late radiation
toxicity criteria (Miller et al, 1981).
Statistics
Survival was measured from first day of chemotherapy until death,
loss to follow-up or time of evaluation for this report. Event-free
survival was calculated from first day of chemotherapy until any
event occurring such as tumour progression, incidence of second
cancer, death due to toxicity, secondary conditions or second
malignancy (Green et al, 1994). Survival curves were estimated by
the method of Kaplan and Meier (1958). Differences in curves
between groups of patients were evaluated using a log-rank test
(Mantel et al, 1966).
RESULTS
Patient characteristics
Forty-six consecutive SCLC patients were enrolled at our institution
from June 1991 until July 1995 and all are eligible for this report.
Patient characteristics are given in Table 1. The four stage IIB
patients had large centrally located bulky T3N0-tumours with inva-
sion of the mediastinal/pericardial pleura. There were 19 patients
with positive N2- and ten with N3-lymph nodes, adding up to 29 of
46 patients (63%) with proven mediastinal node disease. Among the
patients with IIIB-disease, ten had T4-disease, six pulmonary artery
invasion and four diffuse mediastinal organ infiltration.
Induction chemotherapy
All 46 patients received at least one chemotherapy cycle. One
patient died during the first cycle due to septicaemia and was not
evaluable for response. One patient with a cerebral infarction
during the first cycle and one patient with an infection after the
second cycle had to be taken off study. All remaining 43 patients
received at least three cycles. Altogether, 134 chemotherapy
cycles have been applicated and only in 16 cycles treatment had to
be postponed for less than 1 week with dose reduction in ten
cycles. All eight patients with stage IB/IIA had the four planned
cycles and thoracotomy performed.
Induction chemoradiotherapy
All 22 patients with stage IIB/IIIA and two further patients with
stage IIIB were planned for a preoperative chemoradiotherapy
induction. Five patients, one due to decline in performance status
and four due to medical reasons, did not proceed to thoracotomy.
Two further patients refused surgery and received boost irradiation
up to 60 Gy. Thus, of overall 24 patients initially planned to
receive the complete preoperative chemoradiation block, this
could be delivered in 22. No interruptions in radiation delivery had
to be made.
Definitive chemoradiotherapy
Of 16 patients with stage IIIB, 14 were initially not planned for
inclusion of surgery. In the first year of the study, four were treated
with four cycles PE and received sequential radiation up to 50 Gy.
Nine of the ten following patients were given concurrrent chemo-
radiation with one cycle simultaneously to radiation (50–60 Gy).
Maximum clinical response
The maximum clinical response to induction was evaluable in 45
patients. Sixteen clinical complete responses (CR) (35%) and 27
partial remissions (PR) (59%) were achieved, adding up to 43
objective responses (94%). Stable disease (NC) was found in two
patients (4%). No patient showed early progression. Most patients
had continuously shrinking tumours after each cycle with
maximum response following the second cycle and ten patients
with further major improvement to chemoradiotherapy (seven PR
converted to CR, three NC converted to PR). There were no signif-
icant differences in response rates and rates of stable disease
between TNM-subgroups or disease stages.
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Table 1 Patient characteristics
Characteristic No. %
All patients 46 100
Stage
IB T2N0 6 13
IIA T2N1 2 4
IIB T3N0 4 9
IIIA 18 39
T3N1 2
T2N2 10
T3N2 6
IIIB 16 35
T4N0/N1 3
T4N2 3
T2N3 3
T3N3 3
T4N3 4
Age, years
Median 55
Range 34–69
Sex
Male 32 70
Female 14 30
Performance status, WHO
Median 0
03 5 7 6
11 1 2 4
Histological cell type
Small-cell carcinoma 43 94
Mixed small-cell/large-cell 3 6
Lactate dehydrogenase Median (U/l) 213
Range (U/I) 110–393Eligibility for thoracotomy and surgical outcome
Thirty-two patients – all of stages IB–IIIA and two of stage IIIB –
were planned for inclusion of surgery. In 16 patients with involved
mediastinal nodes, repeat mediastinoscopy was performed before
consideration of surgery (14 in stage IIIA and two in IIIB). In three
patients with stage IIIA, positive N2-nodes were found and surgery
was no longer found appropriate. Thus, 13 of 16 patients (81%) with
initially positive mediastinal nodes had an N0-status after the induc-
tion. No patient with N0 at repeat mediastinoscopy had microscopic
N2-status in his final pathology. At the end of induction
chemotherapy±chemoradiation, 24 of the planned 32 patients (75%)
could be operated on (Table 2). One patient turned out irresectable
with multiple pleural metastases. In all remaining 23 (72% of patients
planned for surgery) the primary tumour could be completely
resected. Surgical procedures were: ten pneumonectomies, two
bilobectomies and 11 lobectomies. Of these 23 completely resected
patients, 12 (52%) had viable tumour tissue (five with microscopic,
seven with macroscopic tumour). Histological examinations revealed
nine patients with vital pure small-cell carcinoma and three with non-
small-cell pathology – two with squamous cell and one with large-
cell anaplastic carcinoma. 11 patients (34% of those eligible for
surgery) had no vital tumour in resected specimens (pathological
complete response – pCR) (Table 2).
Toxicities
Maximum toxicity in all 46 patients during induction is listed in
Table 3. Grade 4 haematologic toxicity occurred in 12 (26%).
Severe oesophagitis (grade 3) occurred in five patients, but was
usually of short duration (< 10 days). Three required intravenous
hydration with grade 4 oesophagitis, but radiation was not inter-
rupted and oesophagitis completely recovered within 1 week. No
oesophageal stricture was observed. One patient died due to septi-
caemia during the first chemotherapy cycle. Additional grade 3
toxicities were hearing loss (one patient), peripheral neuropathy
(one patient) and renal impairment (one patient). No peri- or post-
operative deaths occurred. No stump insufficiency or pleural
empyema was observed. Four patients received platelet trans-
fusions due to serious thrombocytopenia, six patients received
erythrocyte transfusions due to symptomatic anaemia and three
had to be taken on antibiotics for fever and infection. Pneumonitis
of grade 3 was seen in two patients. To summarize, only one
patient (2%) died from causes that could be directly attributed to
this intensive multimodality treatment.
Survival
The median follow-up for all patients was 53 months and 52 for
those alive at the time of this report (assessed 1 December 1997).
Median survival for all 46 eligible patients was 36 months and
actuarial 5-year survival was 46% (Figure 2). Median event-free
survival was 24.5 months with 5-year event-free survival of 36%.
The last events at 37, 38 and 40 months were second respiratory
cancers. No SCLC-recurrence was seen after 29 months. Of six
patients with stage IB, three remain alive at 54, 63 and 66 months.
Of two patients with stage IIA, one is alive at 63 months. In 22
patients with stage IIB/IIIA, median survival has not yet been
reached with 5-year survival of 50% and 11 patients alive from 36
to 75 months. In 16 patients with stage IIIB, median survival was
29 months and 5-year survival 35%. Six remain alive at 30–69
months. No significant difference in survival has been observed
between stages IB/IIA, IIB/IIIA and IIIB. Median event-free
survival has been 29 months for stage IIIB, not yet reached in IIA,
33.5 months for IIB/IIIA and 15 months in IIIB (IIB/IIIA versus
IIIB: P = 0.13). No differences in survival and event-free survival
have been observed between different TNM-categories or
subgroups defined by N- and T-parameters, age, sex and initial
LDH-values. CR-patients have a median survival of 28 months
(30% actuarial 5-year survival). Patients with PR have not yet
Prognostically orientated multimodality treatment of LD-SCLC 1209
British Journal of Cancer (1999) 81(7), 1206–1212 © 1999 Cancer Research Campaign
Table 2 Eligibility for thoracotomy and surgical outcome
Patient group No. %
All patients 46
Not planned for surgery (IIIB, CTx+RTx or CTx/RTx) 14
Planned for surgery (stages IB–IIIB) 32 100
Not operable (medical, refusal) 8
Operable 24 24/32 75%
Completely resected (R0) 23 23/32 72%
Resection of vital tumour tissue 12 12/32 38%
Macroscopic tumour 7
Microscopic tumour 5
Small-cell histology 9
Non-small-cell histology 3
Pathological complete response (pCR) 11 11/32 34%
Table 3 Maximum toxicity during chemotherapy ± chemoradiotherapy
WHO grade (n = 46)
Toxicity 1 2 3 4 5
Haematological
Leukocytopenia 6 11 22 6 0
Thrombocytopenia 6 16 10 5 0
Anaemia 11 24 8 1 0
Non-haematological
Fever/infection 4 5 3 0 1
Nausea and vomiting 12 27 3 0 0
Neurological 39 5 1 0 0
Oesophagus 17 14 5 3 0
Lung 19 9 2 0 0
Heart 8 2 1 0 0
Ototoxicity 1 0 1 0 0
Renal 12 2 1 0 0
Other 12 6 0 0 0
Worst effect reported per patient 2 12 23 8 1
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Figure 2 Survival durations (SD) and event-free survival durations (EFSD)
in all patients. SD = survival duration; EFSD = event-free survival duration;
mths = months; 5-Y-SR = 5-year survival ratereached median survival (59% at 34 months). Of two NC patients
one remains alive following R0-resection at 40 months.
Outcome of patients with complete resection (RO)
Patients with complete resection (R0) had a median survival of 68
months and a 5-year survival of 63%. Patients in whom complete
resection was not part of treatment, had a significantly shorter
median survival of 17 months and a 5-year survival of 30%
(P = 0.01). Among patients with R0-resection, no differences in
long-term survival were found between those with pCR and those
with persistent viable tumour (5-year-survival rate 73% vs 57%,
P = 0.75). Actuarial event-free survival has stabilized at 51% after
5 years for all R0-patients and 58% after 5 years for R0-patients of
stages IIB, IIIA and IIIB (Figures 3 and 4). Of these completely
resected patients 12 remain alive and event-free between 34 and
75 months.
Relapse pattern
Of the 23 R0-patients, nine (36%) have relapsed. The only site of
relapse was distant metastases: eight with isolated central nervous
system (CNS) relapse and one with liver metastases. No patient
experienced local/locoregional failure. Two patients developed
second primaries – one in the contralateral middle lobe and one
tracheal carcinoma. Locoregional relapse was seen if complete
resection was not part of treatment. Six of 23 patients (26%) in this
subgroup experienced locoregional failure as first site of relapse,
four of these as the only location of failure. Twelve of 23 patients
(52%) developed distant metastases as first relapse, only in two
patients simultaneously to locoregional failure. Again, the brain
was the most frequent relapse site, with seven of 23 patients (30%)
as first site of failure. One patient in this cohort experienced a
second primary in the respiratory tract (non-small-cell lung
cancer).
DISCUSSION
The present trial investigated feasibility, toxicity and efficacy of
a prognostically orientated multimodality treatment including
surgery for selected SCLC-patients. Entered were stages IB–IIIB,
without malignant effusions or supraclavicular node involvement,
although the majority presented with bulky tumours and proven
mediastinal disease at staging mediastinoscopy. Our results
showed high resectability rates in stages IB–IIIA after
chemotherapy plus/minus chemoradiotherapy. No major perioper-
ative morbidity nor any post-operative mortality was observed that
may be attributed to a consequent protection of bronchial anasto-
mosis intraoperatively (Eberhardt et al, 1998). With mature long-
term follow-up, the median survival for the whole patient cohort of
36 months and an actuarial survival rate of 46% at 5 years are
clearly encouraging.
So far, the best results for SCLC patients have been reported
from combined (concurrent) chemoradiation protocols with
median survival between 18 and 25 months and 5-year survival of
15–25%, but these were groups with limited disease, not generally
excluding positive pleural effusions or involved supraclavicular
nodes (McCracken et al, 1990; Turrisi et al, 1992). Twice daily
thoracic radiotherapy – included early in the treatment – has been
convincingly demonstrated to have an effect on both local control
and long-term survival (Turrisi et al, 1999). A different approach
intensifies the systemic component (chemotherapeutic dose-
intensities) supported by autologous bone marrow or peripheral
stem cell transplantation (Elias et al, 1997; Fetscher et al, 1997). A
small pilot trial in selected patients reported a median survival of
29 months and 5-year survival of 52%, but also observed a
remarkably high local-failure rate (Elias et al, 1993). However,
high-dose treatment may not be possible in most elderly lung
cancer patients and can lead to increased toxicities with mortality
rates reported up to 13% (Fetscher et al, 1997).
A major systemic risk for SCLC patients with prolonged
survival duration has turned out to be development of brain metas-
tases. A carefully performed meta-analysis of published random-
ized trials demonstrated a significant effect of prophylactic cranial
irradiation (PCI) on survival in patients with complete response
(Arriagada et al, 1998).
In contrast, insufficient local control at bulky tumour areas can
be another reason for eventual recurrence. Even after three to four
chemotherapy cycles a rate of vital residual disease at the primary
site between 55 and 80% has been found at adjuvant surgery
(Shepherd et al, 1996). Interestingly, some of the resected speci-
mens demonstrate a change to NSCLC-histopathologies – whether
treatment induced or simply a result of initial tumour cell hetero-
geneity is still not clear (Shepherd et al, 1988). Some investigators
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Figure 3 Event-free survival duration in completely resected patients and
patients not completely resected – stages IB–IIIB. R0-Res. = R0-(complete)
resection; mths = months; 5-Y-EFS = 5-year event-free survival;
nyr = not yet reached
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Figure 4 Event-free survival durations in completely resected patients and
patients without complete resection – stages IIB/IIIA/IIIB only. R0-Res = R0-
(complete)resection; mths = months; 5-Y-EFS = five-year event-free survival;
nyr = not yet reachedhave given chemotherapy preoperatively to stages I–IIIA
(Shepherd et al, 1989; Zatopek et al, 1991; Müller et al, 1992),
others post-operatively (Macchiarini et al, 1989; Ulsperger et al,
1991; Davis et al, 1993). Modern cisplatin-based chemotherapy
was rarely used and different policies concerning integration of
radiotherapy were chosen. Only one study has given a bimodal
induction combining chemotherapy and radiotherapy, but the
patient number finally operated on was too small to draw conclu-
sions (Gridelli et al, 1994).
The only randomized trial testing surgery following induction
chemotherapy came from the Lung Cancer Study Group (LCSG).
After five chemotherapy cycles, responding patients were random-
ized to receive either chest radiotherapy or surgery followed by
radiotherapy (Lad et al, 1994). Preliminary results of this trial did
not support the use of surgery in comparable patient subgroups.
However, the patient selection of the LCSG-trial was not compa-
rable to the one in our study. The LCSG did not include staging
mediastinoscopy, patients were not a priori assessed to be
resectable and were randomized only following response to
chemotherapy. Moreover, this trial has also been criticized
concerning its final conclusions and consequences (Shepherd et al,
1996).
On this background, we reconsidered surgery as definitive local
treatment following induction chemotherapy plus/minus concur-
rent chemoradiotherapy in stages IB–IIIA. Of note is the high rate
of 100% locoregional control following complete resection.
Median survival of 68 months and a 5-year survival of 63% in this
subgroup are promising and point to the efficacy of this approach
also in patients in stage IIIA (N2). Different to our findings
with preoperative chemoradiation, earlier investigations with
chemotherapy alone followed by surgery had been disappointing
for mediastinal N2-disease (IIIA(N2)) (Meyer et al, 1984;
Shepherd et al, 1993).
In conclusion, surgery in SCLC can be considered in stages IB
and IIA following chemotherapy, but has also demonstrated to be
feasible in stages IIB and IIIA following induction chemoradio-
therapy. Its definitive value on local control or long-term prognosis
could only be evaluated in a further randomized trial that is urgently
needed in this disease with overall poor long-term results and in
which the impact of local control may have been underestimated.
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